VivoSeq
Psychiatry

Panic Disorder

36

Pipeline Programs↗

2

Active Trials↗

20

Companies Involved↗

Panic Disorder is a moderately active landscape with 36 programs across 20 companies. The most active players are Honeybrains Biotech LLC, Nobilis Therapeutics Inc., Merck & Co.. 19 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

0/100

Mech. Concentration

38/100

Completion Rate

81/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Honeybrains Biotech LLC

4 programs

Phase 2N

Nobilis Therapeutics Inc.

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2C

Cerevel Therapeutics, LLC

1 program

Phase 2UCB logo

UCB

1 program

Phase 3AbbVie logo

AbbVie

2 programs

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

44

clinical trials

Completed29 · 66%
Terminated7 · 16%
Unknown status6 · 14%
Not yet recruiting1 · 2%
Recruiting1 · 2%

Clinical Trials

Trial Activity

44 trials

Efficacy and Safety of HB-1 for Panic Disorder
Recruiting·HHoneybrains Biotech LLC·Phase 2·NCT06483789·240 enrolled
Efficacy of Hydroxyzine for Patients With Panic Disorder
Not yet recruiting·SSultan Qaboos University·Phase 4·NCT05737511·80 enrolled
Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks
Completed·LLindner Center of HOPE·Phase 3·NCT00279617·15 enrolled
Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder
Completed·SSamsung Medical Center·Phase 4·NCT00767871·46 enrolled
Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression
Completed·National Institute of Mental Health (NIMH)·Phase 4·NCT00031317·60 enrolled
Special Drug Use Investigation for PAXIL Tablet (Pediatric Panic Disorder)
Completed·GSK logoGSK·N/A·NCT01376128·96 enrolled
Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder
Completed·—·Phase 2·NCT00790868·180 enrolled
Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F]SPA-RQ
Completed·National Institute of Mental Health (NIMH)·Phase 1·NCT00088738·84 enrolled
Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder
Completed·Pfizer logoPfizer·Phase 3·NCT00195598·70 enrolled
Treatment of Panic Disorder: Long Term Strategies
Completed·NNew York State Psychiatric Institute·Phase 3·NCT00000368·379 enrolled
Randomized Study of Cognitive-Behavioral Therapy vs Imipramine and Their Combination for Panic Disorder
Completed·NNorthwell Health·N/A·NCT00004834·326 enrolled
The Role of Orexin in Human Panic Disorder
Completed·UUniversity of California, San Francisco·Phase 4·NCT02593682·3 enrolled
Safety and Efficacy of HB-1 for Panic Disorder
Completed·HHoneybrains Biotech LLC·Phase 2·NCT05071430·86 enrolled
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder
Completed·AbbVie logoAbbVie·Phase 2·NCT05941442·80 enrolled
Study Evaluating Venlafaxine ER in Adults With Panic Disorder
Completed·Pfizer logoPfizer·Phase 3·NCT00038896·343 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)